LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

Home・Stock List・AbbVie Inc

AbbVie Inc

Closed

Sector Healthcare

182.14 3.37

Buy Sell

Overview

Share price change

24h

Current

Min

171.01

Max

185.88

Key metrics
By Trading Economics
Income	547M 1.4B
Sales	-2B 12B
P/E Sector Avg	42.514 79.786
EPS	2.31
Profit margin	11.121
Employees	50,000
EBITDA	-2.3B 4.5B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+6.95 upside

Dividends
By Dow Jones
Next Dividend date	15 Aug 2024
Next Ex Dividend date	10 Oct 2024

Market Stats
By TradingEconomics
Market Cap	815M 298B
Previous open	178.77
Previous close	182.14

News Sentiment

By Acuity

34%

66%

74 / 369 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

169.91 / 176.68 Support & Resistance

AbbVie Inc Chart

Related News

25 Jul 2024, 12:18 UTC

Earnings

AbbVie 2Q Revenue Gets Boost From Skyrizi, Rinvoq Sales

27 Jun 2024, 13:58 UTC

Acquisitions, Mergers, Takeovers

AbbVie Buys Celsius Therapeutics for $250 Million

26 Apr 2024, 20:53 UTC

Major Market Movers

AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q

26 Apr 2024, 12:25 UTC

Earnings

AbbVie Lifts Outlook After 1Q Revenue Unexpectedly Rises

25 Jul 2024, 13:01 UTC

Earnings

AbbVie Slides Despite Beating Second-Quarter Views, Raising Guidance -- IBD

25 Jul 2024, 12:46 UTC

Peer Comparison

Price change

AbbVie Inc Forecast

Price Target

By TipRanks

6.95% upside

12 Months Forecast

Average 188.46 USD 6.95%

High 214 USD

Low 172 USD

Based on 15 Wall Street analysts offering 12 month price targets forAbbVie Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Based on 15 analysts giving stock ratings to AbbVie Inc - Dist in the past 3 months.

Technical Score

By Trading Central

169.91 / 176.68Support & Resistance

Recent bullish events outweigh bearish events.

There is one bullish event.

Sentiment

By Acuity

74 / 369 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.